Wet granulation of co-amorphous indomethacin systems

被引:0
作者
Schutz, David [1 ]
Timmerhaus, Annika [1 ]
Grohganz, Holger [1 ,2 ]
机构
[1] Univ Copenhagen, Dept Pharm, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Pharm, Univ Pk 2, DK-2100 Copenhagen O, Denmark
关键词
Amino acid; Co-amorphous; Downstream processing; Molecular interactions; Solid state; Wet granulation; WATER-SOLUBLE DRUGS; AMINO-ACIDS; DISSOLUTION BEHAVIOR; PHYSICAL STABILITY; SOLUBILITY; NAPROXEN; ARGININE; STATE;
D O I
10.1016/j.ijpharm.2023.123318
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The feasibility of co-amorphous systems to be wet granulated together with microcrystalline cellulose (MCC) was investigated. Solid state and molecular interactions were analysed for various coamorphous drug-amino acid formulations of indomethacin with tryptophan and arginine, respectively, via XRPD, DSC and FTIR. The co -amorphous binary systems were produced by ball-milling for 90 min at different molar ratios followed by wet granulation with MCC and water in a miniaturised scale. Tryptophan containing systems showed crystalline reflections in their XRPD diffractograms and endothermal events in their DSC analyses, and were therefore excluded from upscaling attempts. The systems containing arginine were found to be remain amorphous for at least ten months and were upscaled for production in a high-shear blender under application of two different parameter settings. Under the harsher instrument settings, a composition with a low MCC ratio experienced recrystallisation during wet granulation, while all other compositions could be successfully processed via wet granulation and stayed stable for a storage period of at least twelve weeks, indicating that wet granulation of co -amorphous systems can be feasible.
引用
收藏
页数:9
相关论文
共 46 条
  • [1] Ali J, 2010, J YOUNG PHARM, V2, P3, DOI [10.4103/0975-1483.62205, 10.4103/0975-1483.51868]
  • [2] Amorphous carbamazepine stabilization by the mesoporous silicate SBA-15
    Ambrogi, Valeria
    Marmottini, Fabio
    Pagano, Cinzia
    [J]. MICROPOROUS AND MESOPOROUS MATERIALS, 2013, 177 : 1 - 7
  • [3] Co amorphous systems: A product development perspective
    Chavan, Rahul B.
    Thipparaboina, Rajesh
    Kumar, Dinesh
    Shastri, Nalini R.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 515 (1-2) : 403 - 415
  • [4] Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy
    Cruz-Angeles, Jorge
    Videa, Marcelo
    Maria Martinez, Luz
    [J]. AAPS PHARMSCITECH, 2019, 20 (04)
  • [5] Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization
    da Costa, Nuno F.
    Daniels, Rolf
    Fernandes, Ana, I
    Pinto, Joao F.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [6] Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
    da Costa, Nuno F.
    Daniels, Rolf
    Fernandes, Ana I.
    Pinto, Joao F.
    [J]. PHARMACEUTICS, 2022, 14 (08)
  • [7] Bridging solubility between drug discovery and development
    Di, Li
    Fish, Paul V.
    Mano, Takashi
    [J]. DRUG DISCOVERY TODAY, 2012, 17 (9-10) : 486 - 495
  • [8] Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability
    Fael, Hanan
    Demirel, A. Levent
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 600
  • [9] Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior
    Fael, Hanan
    Demirel, A. Levent
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 581
  • [10] Arginine: Its pKa value revisited
    Fitch, Carolyn A.
    Platzer, Gerald
    Okon, Mark
    Garcia-Moreno E, Bertrand
    McIntosh, Lawrence P.
    [J]. PROTEIN SCIENCE, 2015, 24 (05) : 752 - 761